Pune-based drugmaker Brinton Pharmaceuticals Ltd has raised Rs 25.6 crore ($4 million) from Tata Capital Healthcare Fund, the healthcare-focused arm of private equity firm Tata Capital Ltd.
The investment will help Brinton enter new areas such as pediatrics and gynecology. It will also help it expand its international operations to 32 countries compared with eight currently.
Brinton, which was founded in 2013, offers clinical and cosmetic dermatology formulations in therapy areas such as anti-fungal, topical corticosteroids, anti-acne, skin care emollients and hair care. Within a year, it became one of the fastest growing companies in the dermatology segment in India.
The company expects its revenues from the dermatology segment to cross Rs 300 crore by FY2020-21.
Brinton has a field workforce of 400 in India. Its operations are also spread across French-speaking countries and West Africa besides Nepal, Sri Lanka and Bangladesh.
